Clinical Trials in New York State

Showing 6821-6840 of 13,041 trials

A Study to Evaluate the Pain Relieving Effects, Safety, and Tolerability of JNJ-42160443 for the Relief of Bladder Pain

NCT01060254

The purpose of this study is to evaluate the analgesic efficacy, safety, and tolerability of JNJ-42160443 compared to placebo in patients with moderate to severe, chronic bladder pain from interstitial cystitis and/or painful bladder syndrome.

Cystitis, InterstitialUrologic DiseasesUrinary Bladder Diseases+1 more

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.31 participantsStarted Apr 2010

Birmingham, Alabama, United States • Phoenix, Arizona, United States • Glendora, California, United States +22 more locations

COMPLETEDPhase 264 miles

Therapy With Bevacizumab (BEV), Epirubicin, and Cyclophosphamide Followed by Docetaxel Plus Trastuzumab and BEV Given as Neoadjuvant or Adjuvant Therapy for Women With Locally Advanced HER2 Positive Invasive Breast Cancer

NCT00464646

The main purpose is to learn if adding bevacizumab to standard chemotherapy and trastuzumab to treat HER2-positive breast cancer will affect heart function. This study will evaluate: * How bevacizumab, given with chemotherapy, and then bevacizumab given with trastuzumab after surgery, will affect breast tumors * Side effects from adding bevacizumab to chemotherapy and trastuzumab * Whether adding bevacizumab to chemotherapy and trastuzumab for breast cancer will affect the heart * If receiving bevacizumab will have any effect on how patients recover from surgery

Breast Cancer

NSABP Foundation Inc105 participantsStarted May 2007

Huntsville, Alabama, United States • San Diego, California, United States • Vallejo, California, United States +33 more locations

A Study to Evaluate the Pain Relieving Effects, Safety, and Tolerability of JNJ-42160443 for the Relief of Bladder Pain

Therapy With Bevacizumab (BEV), Epirubicin, and Cyclophosphamide Followed by Docetaxel Plus Trastuzumab and BEV Given as Neoadjuvant or Adjuvant Therapy for Women With Locally Advanced HER2 Positive Invasive Breast Cancer

Find Trials by Condition in New York State

Triathlon Total Stabilizer (TS) Outcomes Study

Tolvaptan Extension Study in Participants With ADPKD

Safety and Effectiveness of an Adjuvant in Improving Immune Response to Hepatitis B Virus Vaccine in HIV Infected Individuals

Comparison of Adenoma Detection Rate With ENDOCUFF VISION® vs. G-EYE®

RAD001 for Patients With Radioiodine Refractory Thyroid Cancer

Dalantercept in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer

Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion

Study of Nivolumab, Cabiralizumab, and Stereotactic Body Radiotherapy (SBRT) for Locally Advanced Unresectable Pancreatic Cancer

Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain Tumors

Convalescent Plasma in Outpatients With COVID-19

The BROADEN Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Participants With Familial Partial Lipodystrophy

Treatment Seeking Study

Safety and Efficacy of BRM421 for Dry Eye Syndrome Treatment

Safety and Efficacy Study of Lucanthone When Used in Combination With Temozolomide(TMZ) and Radiation to Treat Glioblastoma Multiforme(GBM)

Global Epidemiologic Study of Preexisting Immunity to AAV in Adults With Severe Hemophilia

Study of CX-4945 in Combination With Gemcitabine and Cisplatin for Frontline Treatment of Cholangiocarcinoma

Non-interventional Post-authorisation Study to Document the Immunogenicity, Safety, and Efficacy of NUWIQ

Study of Estrogen Levels in Premenopausal Women Who Have Undergone Surgery for Breast Cancer and Are Receiving Triptorelin and Tamoxifen Citrate or Exemestane on Clinical Trial IBCSG 24-02